Skip to main content

Table 4 Relative gene expression of the 15 genes comprising the pre-treatment signature comparing responders in the discovery dataset to healthy volunteers and to non-responders

From: Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab

15-Gene Pre-Treatment Model Predictor or Enhancer Variable Blood Bank Difference Normals versus Responders Phase 3 Discovery Dataset  
N = 50 N = 28 N = 182 Difference
Healthy Normals Responders Non-Responders Responders vs Non-responders
Responders Equivalent to Normals
 ITGA4 Predictor 14.2 0.02 14.22 14.61 0.39
 LARGE Predictor 22.0 0.09 22.09 22.97 0.88
 CDK2 Predictor 19.6 0.09 19.69 19.91 0.22
 TIMP1 Enhancer 15.0 0.10 15.1 14.95 −0.15
 DPP4 Predictor 18.5 0.12 18.62 18.95 0.33
 NRAS Predictor 17.1 0.13 17.23 17.44 0.21
 ERBB2 Predictor 23.0 −0.18 22.82 23.23 0.41
 NAB2 Predictor 20.0 −0.29 19.71 20.04 0.33
Responders Upregulated Compared to Normals
 ADAM17 Enhancer 18.5 0.32 18.18 18.36 0.18
 RHOC Enhancer 16.9 0.39 16.51 16.63 0.12
 TGFB1 Enhancer 13.4 0.45 12.95 13.05 0.10
 CDKN2A Predictor 21.4 0.63 20.77 21.16 0.39
Responders Downregulated Compared to Normals
 HLADRA Enhancer 12.1 0.48 12.58 12.64 0.06
 MYC Enhancer 17.7 0.82 18.53 18.67 0.14
Measurement of Gene Expression Not Available
 ICOS Predictor N/A N/A 22.32 22.78 0.46